Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib

Ectopic hepatocellular carcinoma (HCC) is a rare malignancy, which manifests similar morphology and immunohistochemistry to intrahepatic HCC. Herein, we report a case of ectopic HCC in a 73-year-old male. The patient presented to our hospital with gradually progressing right lower abdominal pain, an...

Full description

Saved in:
Bibliographic Details
Published inCase reports in gastroenterology Vol. 14; no. 1; pp. 226 - 233
Main Authors Ko, Yi-Ling, Takata, Kazuhide, Tanaka, Takashi, Ohishi, Jun, Takeshita, Morishige, Yamauchi, Ryo, Fukuda, Hiromi, Miyayama, Takashi, Uchida, Yotaro, Yokoyama, Keiji, Morihara, Daisuke, Takeyama, Yasuaki, Shakado, Satoshi, Sakisaka, Shotaro, Hirai, Fumihito
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.01.2020
Karger Publishers
Subjects
Abdomen
Alcohol
Anemia
Biopsy
Case reports
Diabetes
ectopic hcc
Enzymes
Heat shock proteins
Hepatitis B
Inhibitor drugs
Laboratories
Liver cancer
Magnetic resonance imaging
Medical prognosis
Prostate
Single Case
sorafenib
Stains & staining
Targeted cancer therapy
Tumors
tyrosine kinase inhibitor
Ultrasonic imaging
Ectopic HCC
Tyrosine kinase inhibitor
Sorafenib
Online AccessGet full text

Cover

More Information
Summary:Ectopic hepatocellular carcinoma (HCC) is a rare malignancy, which manifests similar morphology and immunohistochemistry to intrahepatic HCC. Herein, we report a case of ectopic HCC in a 73-year-old male. The patient presented to our hospital with gradually progressing right lower abdominal pain, and enhanced computed tomography revealed multiple nodules in the peritoneum without intrahepatic mass. A diagnostic laparoscopy was performed, and the final pathology result confirmed that it was HCC. Additional laboratory tests showed elevated serum alpha-fetoprotein and protein induced by vitamin K absence-II (PIVKA-II) levels, suggesting our diagnosis. The patient received sorafenib, a tyrosine kinase inhibitor (TKI), for unresectable ectopic HCC. However, the tumor progressed, and because of tarry stools and hemorrhagic anemia, sorafenib was ceased after 7 months of therapy. One month after the cessation of sorafenib, the PIVKA-II level increased abruptly, and the patient died 1 year after diagnosis. The effective treatment for unresectable ectopic HCC is still unknown. Additional cases should be accumulated to determine the effect of TKI on ectopic HCC.
ISSN:1662-0631
1662-0631
DOI:10.1159/000506929